Sanofi-Aventis does not intend to buy U.S. biotechnology company ImClone Systems, the French drugmaker said on Wednesday.
"Following numerous articles in the French and international press regarding Imclone ... (Sanofi) wants to state the following: Sanofi has not made an offer for Imclone and does not intend to make one," a Sanofi-Aventis spokeswoman told Reuters.
ImClone, best known for its Erbitux cancer drug, said on Oct. 4 it had received a takeover proposal from an unnamed big drugmaker but added that billionaire investor Carl Icahn had sabotaged the deal.
The New York Times on Tuesday identified Sanofi as the suitor, citing people involved in the transaction.
Meanwhile, ImClone's Chairman David Kies resigned, pressured by Icahn, who considers the company's management incompetent and is seeking to win control of the board.
Sanofi-Aventis shares fell 0.8 percent to 68.60 euros by 0816 GMT, while the DJ health index slipped 0.2 percent.
"Following numerous articles in the French and international press regarding Imclone ... (Sanofi) wants to state the following: Sanofi has not made an offer for Imclone and does not intend to make one," a Sanofi-Aventis spokeswoman told Reuters.
ImClone, best known for its Erbitux cancer drug, said on Oct. 4 it had received a takeover proposal from an unnamed big drugmaker but added that billionaire investor Carl Icahn had sabotaged the deal.
The New York Times on Tuesday identified Sanofi as the suitor, citing people involved in the transaction.
Meanwhile, ImClone's Chairman David Kies resigned, pressured by Icahn, who considers the company's management incompetent and is seeking to win control of the board.
Sanofi-Aventis shares fell 0.8 percent to 68.60 euros by 0816 GMT, while the DJ health index slipped 0.2 percent.
posted by doublezero at
9:02 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home